Treatment Outcomes After Proton Therapy for Ewing Sarcoma of the Pelvis
- PMID: 32437922
- DOI: 10.1016/j.ijrobp.2020.04.043
Treatment Outcomes After Proton Therapy for Ewing Sarcoma of the Pelvis
Abstract
Purpose: Ewing sarcoma of the pelvis is associated with inferior local control compared with those arising from other primary sites. Despite its increased use, outcome data for treatment with proton therapy remain limited. We report 3-year disease control and toxicity in pediatric patients treated with proton therapy.
Methods and materials: Thirty-five patients aged ≤21 years (median, 14 years) with nonmetastatic pelvic Ewing sarcoma received proton therapy and chemotherapy between 2010 and 2018. Overall survival and tumor control rates were calculated using the Kaplan-Meier method. A log-rank test assessed significance between strata of prognostic factors. Significant toxicity was reported per the Common Terminology Criteria for Adverse Events, version 4.0.
Results: Most patients received definitive radiation (n = 26; median dose 55.8 Gy relative biological effectiveness [RBE]; range, 54.0-64.8), 7 received preoperative radiation (50.4 Gy RBE), and 2 received postoperative radiation (45 Gy RBE and 54 Gy RBE). The median primary tumor size was 10.5 cm. With a median follow-up of 3 years (range, 0.3-9.0 years), the 3-year overall survival, progression-free survival, and local control rates were 83% (95% confidence interval [CI], 65%-93%), 64% (95% CI, 45%-79%), and 92% (95% CI, 74%-98%), respectively. There was no association between local control, progression-free survival, or overall survival and tumor size, patient age, radiation dose, or definitive versus pre-/postoperative radiation therapy. Median time to progression was 1 year (range, 0.1-1.9 years). All patients with large tumors (≥8 cm) who underwent definitive proton therapy with a higher dose (≥59.4 Gy RBE) remained free from tumor recurrence (n = 5). Five patients experienced grade ≥2 subacute/late toxicity, all of whom were treated with combined surgery and radiation.
Conclusions: Definitive proton therapy offers local control comparable to photon therapy in pediatric patients with pelvic Ewing sarcoma. These data lend preliminary support to radiation dose escalation without significant toxicity, which may contribute to the favorable outcomes. Combined surgery and radiation therapy, particularly preoperative radiation, is associated with postoperative complications, but not survival, compared with radiation alone.
Copyright © 2020 Elsevier Inc. All rights reserved.
Comment in
-
In Pediatric Sarcomas, Less is Sometimes More.Int J Radiat Oncol Biol Phys. 2022 Aug 1;113(5):907-910. doi: 10.1016/j.ijrobp.2022.03.035. Int J Radiat Oncol Biol Phys. 2022. PMID: 35841914 No abstract available.
Similar articles
-
Comprehensive radiotherapy for pediatric Ewing Sarcoma: Outcomes of a prospective proton study.Radiother Oncol. 2024 Jun;195:110270. doi: 10.1016/j.radonc.2024.110270. Epub 2024 Apr 5. Radiother Oncol. 2024. PMID: 38583721
-
Pencil beam scanned protons for the treatment of patients with Ewing sarcoma.Pediatr Blood Cancer. 2017 Dec;64(12). doi: 10.1002/pbc.26688. Epub 2017 Jun 19. Pediatr Blood Cancer. 2017. PMID: 28627000
-
Outcomes following proton therapy for Ewing sarcoma of the cranium and skull base.Pediatr Blood Cancer. 2020 Feb;67(2):e28080. doi: 10.1002/pbc.28080. Epub 2019 Nov 17. Pediatr Blood Cancer. 2020. PMID: 31736243
-
Modern Therapy for Spinal and Paraspinal Ewing Sarcoma: An Update of the University of Florida Experience.Int J Radiat Oncol Biol Phys. 2022 May 1;113(1):161-165. doi: 10.1016/j.ijrobp.2022.01.007. Epub 2022 Jan 13. Int J Radiat Oncol Biol Phys. 2022. PMID: 35033584 Review.
-
The Children's Oncology Group Radiation Oncology Discipline: 15 Years of Contributions to the Treatment of Childhood Cancer.Int J Radiat Oncol Biol Phys. 2018 Jul 15;101(4):860-874. doi: 10.1016/j.ijrobp.2018.03.002. Epub 2018 Mar 14. Int J Radiat Oncol Biol Phys. 2018. PMID: 29976498 Free PMC article. Review.
Cited by
-
Pediatric Experience and Outcomes from the First Single-Vault Compact Proton Therapy Center.Cancers (Basel). 2023 Aug 12;15(16):4072. doi: 10.3390/cancers15164072. Cancers (Basel). 2023. PMID: 37627100 Free PMC article.
-
Radiotherapy in bone sarcoma: the quest for better treatment option.BMC Cancer. 2023 Aug 11;23(1):742. doi: 10.1186/s12885-023-11232-3. BMC Cancer. 2023. PMID: 37563551 Free PMC article. Review.
-
Pragmatic, Prospective Comparative Effectiveness Trial of Carbon Ion Therapy, Surgery, and Proton Therapy for the Management of Pelvic Sarcomas (Soft Tissue/Bone) Involving the Bone: The PROSPER Study Rationale and Design.Cancers (Basel). 2023 Mar 8;15(6):1660. doi: 10.3390/cancers15061660. Cancers (Basel). 2023. PMID: 36980545 Free PMC article.
-
Particle Therapy in Adult Patients with Pelvic Ewing Sarcoma-Tumor and Treatment Characteristics and Early Clinical Outcomes.Cancers (Basel). 2022 Dec 8;14(24):6045. doi: 10.3390/cancers14246045. Cancers (Basel). 2022. PMID: 36551530 Free PMC article.
-
Management of Unresectable Localized Pelvic Bone Sarcomas: Current Practice and Future Perspectives.Cancers (Basel). 2022 May 22;14(10):2546. doi: 10.3390/cancers14102546. Cancers (Basel). 2022. PMID: 35626150 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical